VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NBIX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NBIXNeurocrine Biosciences, Inc.
$162.86$16.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNBIXP/E History

NBIX logoNeurocrine Biosciences, Inc. (NBIX) P/E Ratio History

Deep Value

Trading at 24.4x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 1996–2026

Current P/E (TTM)
24.4x
-76% vs 5Y avg
5Y Avg P/E
102.2x
Median 41.6x
5Y Percentile
10th
Lower end of range
PEG Ratio
10.42
Premium to growth
5-Year P/E Range
24.4x
Min20.3xMedian41.6xMax861.9x
TTM EPS$6.68
Price$162.86
Earnings Yield4.10%
EPS Growth (1Y)41.9%
EPS Growth (5Y)2.3%

Loading P/E history...

P/E Ratio Analysis

As of November 19, 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a price-to-earnings ratio of 24.4x, with a stock price of $162.86 and trailing twelve-month earnings per share of $6.68.

The current P/E is 76% below its 5-year average of 102.2x. Over the past five years, NBIX's P/E has ranged from a low of 20.3x to a high of 861.9x, placing the current valuation at the 10th percentile of its historical range.

Compared to the Healthcare sector median P/E of 24.7x, NBIX is roughly in line with its sector peers. The sector includes 252 companies with P/E ratios ranging from 0.0x to 187.0x.

The PEG ratio of 10.42 (P/E divided by 42% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, NBIX trades roughly in line with the S&P 500 median P/E of 21.7x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NBIX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

NBIX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
24.4vs24.7
-1%
In Line with Sector
vs. S&P 500
24.4vs21.7
+12%
Above Market
PEG Analysis
10.42
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 42% EPS growth (1Y)

NBIX P/E vs Peers

Commercial Neuroscience Biopharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INVA logoINVAInnoviva, Inc.
$1B6.90.66+817%
ACAD logoACADACADIA Pharmaceuticals Inc.
$3B8.6-+68%
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$4B7.9-+10833%Best
INTR logoINTRInter & Co, Inc.
$2B6.2Lowest0.04Best+40%
HRMY logoHRMYHarmony Biosciences Holdings, Inc.
$2B11.1-+8%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

NBIX Historical P/E Data (1996–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q3Sep 30 2026$141.84$6.7421.0x-86%
FY2026 Q2-$168.54$6.8224.7x-84%
FY2026 Q1-$131.74$6.4920.3x-87%
FY2025 Q4Dec 31 2025$141.83$4.6630.4x-80%
FY2025 Q3-$140.38$4.1833.6x-78%
FY2025 Q2Jun 30 2025$125.69$3.3837.2x-76%
FY2025 Q1Mar 31 2025$110.60$2.9537.5x-76%
FY2024 Q4-$136.50$3.2941.5x-73%
FY2024 Q3Sep 30 2024$115.22$3.7330.9x-80%
FY2024 Q2Jun 30 2024$137.67$3.3141.6x-73%
FY2024 Q1Mar 31 2024$137.92$3.6338.0x-75%
FY2023 Q4Dec 31 2023$131.76$2.4254.4x-65%
FY2023 Q3Sep 30 2023$112.50$1.8660.5x-61%
FY2023 Q2Jun 30 2023$94.30$1.7354.5x-65%
FY2023 Q1Mar 31 2023$101.22$0.60168.7x+10%
FY2022 Q4Dec 31 2022$119.44$1.5378.1x-49%
FY2022 Q3Sep 30 2022$106.21$0.57185.3x+20%
FY2022 Q2-$97.48$0.11861.9x+459%
FY2022 Q1-$93.75$0.72129.7x-16%
FY2021 Q4Dec 31 2021$85.17$0.9193.3x-39%
FY2021 Q3-$95.91$4.5721.0x-86%
FY2021 Q2Jun 30 2021$97.32$3.7226.2x-83%
FY2021 Q1Mar 31 2021$97.25$4.1023.7x-85%
FY2020 Q4-$95.85$4.1623.0x-85%
FY2020 Q3Sep 30 2020$96.16$0.93103.4x-33%
FY2020 Q2-$122.00$2.1157.8x-62%
FY2020 Q1-$86.55$1.8447.0x-69%
FY2019 Q4-$107.49$0.33325.7x+111%
FY2019 Q3Sep 30 2019$90.11$0.17530.1x+244%
FY2019 Q2Jun 30 2019$84.43$0.13649.5x+322%
FY2018 Q4Dec 31 2018$71.41$0.17409.5x+166%
FY2018 Q3Sep 30 2018$122.95$0.062091.0x+1257%
FY2012 Q4Dec 31 2012$7.48$0.07103.9x-33%
FY2012 Q2Jun 30 2012$7.89$0.5614.1x-91%
FY2012 Q1Mar 31 2012$7.97$0.6013.2x-91%
FY2011 Q4Dec 31 2011$8.50$0.6712.7x-92%
FY2011 Q3Sep 30 2011$5.98$0.698.6x-94%
FY2011 Q2-$8.05$0.1942.0x-73%
FY2011 Q1-$7.59$0.06121.4x-21%
FY1997 Q4Dec 31 1997$7.88$0.2828.6x-81%
FY1997 Q3-$9.56$0.5318.2x-88%
FY1997 Q2Jun 30 1997$9.00$0.4719.3x-87%
FY1997 Q1Mar 31 1997$9.00$0.5715.8x-90%
FY1996 Q4-$10.00$0.3429.4x-81%

Average P/E for displayed period: 154.1x

Export Data
Consensus & Technical Research Suite
Open NBIX Terminal

NBIX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

30+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NBIX — Frequently Asked Questions

Quick answers to the most common questions about buying NBIX stock.

What is NBIX's P/E ratio?

Neurocrine Biosciences, Inc. (NBIX) trailing twelve-month P/E ratio is 24.4x, based on TTM diluted EPS of $6.68. The 5-year average P/E is 102.2x and the historical range spans 20.3x to 861.9x.

Is NBIX stock overvalued or undervalued?

NBIX trades at 24.4x P/E, below its 5-year average of 102.2x. At the 10th percentile of its historical range (20.3x–861.9x), the stock is priced at a discount to its own history.

Is NBIX stock expensive?

No, NBIX is not expensive on a historical basis. The current P/E of 24.4x is below the 5-year average of 102.2x and sits at the 10th percentile of its valuation range.

What is NBIX's historical P/E range?

Over the past 5 years, NBIX's P/E ratio has ranged from 20.3x to 861.9x, with a median of 41.6x and an average of 102.2x. The current P/E of 24.4x places the stock at the 10th percentile of this range. Full historical data spans 1996–2026.

How does NBIX's P/E compare to the S&P 500?

NBIX trades at 24.4x P/E versus the S&P 500 median of 21.7x. The 12% premium to the market typically reflects higher expected earnings growth or quality.

How does NBIX's valuation compare to Healthcare peers?

Neurocrine Biosciences, Inc. P/E of 24.4x compares to the Healthcare sector median of 24.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is NBIX's PEG ratio?

NBIX PEG ratio is 10.42, based on a P/E of 24.4x and EPS growth of 41.9%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is NBIX's earnings yield?

NBIX earnings yield is 4.10%, the inverse of its 24.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

NBIX P/E Ratio History (1996–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current21.0x
Period Avg102.2x
Range20.3x - 861.9x
Change-77%
20 quartersDec 31, 2021 - Sep 30, 2026